Milad Shirvaliloo

Genetics — Tabriz University of Medical Sciences, Iran

LeadR Profile

Milad Shirvaliloo, MD Tabriz University of Medical Sciences Iran
139 ScienceLeadR Reputation 139
Network Map

Genetics

Subspecialties: Biochemistry - Oncology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Dr. Milad Shirvaliloo is an Iranian physician-researcher with a strong interest in epigenetics, particularly the posttranslational modifications of histone proteins. He holds an MD degree from Tabriz University of Medical Sciences (2023) and maintains active research interests in epigenetics and bioinformatics, with a focus on lung cancer and respiratory infectious diseases. He serves on the Editorial Board of Epigenomics (since 2022) and holds an invited position as a Board Member for Molecular and Cellular Biochemistry. His work integrates clinical perspective with research, and he is committed to authoritative science communication.

Organizations

Career arc: 2023 - 2026

Source: PubMed

Iran University of Medical Sciences

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 52

Citations

Citations: 780 1st author: 3 Last author: 3 Unique author: 11


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery.
cells, pharmaceutical preparations, hyperthermia, brain, neoplasms, drug therapy, glioblastoma, therapeutics, chemotherapy
Med Oncol20243
Sydenham's Chorea in Children with Acute Rheumatic Fever: An Echocardiographic Survey of Pediatric Patients in Northwestern Iran.
rheumatic fever, streptococcal infections, prevalence, sex, chorea, child
Iran J Med Sci20241
Dual-drug delivery by thermo-responsive Janus nanogel for improved cellular uptake, sustained release, and combination chemo-thermal therapy.
technology, pharmaceutical, brain, pharmaceutical preparations, cells, therapeutics, fluorouracil, neoplasms, nanoparticles
Int J Pharm20246
Percutaneous Coronary Intervention Associated with a Higher Risk of Hypoxemia and COVID-19 Severity.
risk, history, chemistry, pharmaceutical, drug design, percutaneous coronary intervention, covid-19
Curr Med Chem20233
Expression and promoter methylation of mitogen-activated protein kinase 1 in tumor and marginal cells of breast cancer.
breast diseases, biomarkers, mitogens, cells, breast neoplasms, mitogen-activated protein kinase 1, mitogen-activated protein kinases, promoter regions, genetic
Breast Dis20230

LeadR Networks

Main global connection map